Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sumitomo Dainippon Pharma Co ( (JP:4506) ) has issued an update.
Sumitomo Pharma Co., Ltd. announced that President and CEO Toru Kimura held a conference on January 30, 2026, to discuss the company’s financial results for the third quarter of fiscal year 2025, covering the period from April 1 to December 31, 2025. The company emphasized that the materials presented include forward-looking information based on current assumptions and estimates, and highlighted that actual performance and development outcomes may differ materially due to various risks and uncertainties, underscoring a cautious stance toward projections and the non-promotional, non-medical-advice nature of product-related information provided.
The most recent analyst rating on (JP:4506) stock is a Buy with a Yen2501.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and sale of prescription drugs and other healthcare-related products, with a portfolio spanning areas such as psychiatry, neurology, oncology and other specialty therapeutic fields in global markets.
Average Trading Volume: 10,215,052
Technical Sentiment Signal: Buy
Current Market Cap: Yen899.1B
For a thorough assessment of 4506 stock, go to TipRanks’ Stock Analysis page.